Plasma samples from patients attending a lipid clinic (n = 14) and healthy control subjects (n = 21) were assayed for fibrinogen using an immunochemical method (radial immunodiffusion) and a turbidimetric assay based on the thrombin clotting technique. The patients had significantly higher plasma fibrinogen concentrations than controls by both methods, but there was significant overlap between the two groups when fibrinogen was assayed by the thrombin clotting technique; there was almost complete separation of the two groups using the immunochemical assay. This difference in overlap could not be attributed to the presence or absence of fibrinogen degradation products. These findings may have important implications for the choice of method for determining plasma fibrinogen when assays are used for the assessment of cardiovascular risk. It is recommended that plasma fibrinogen should be assayed by both an immunochemical and a thrombin clotting method.
Increased plasma fibrinogen concentration has recently been shown to be an independent risk factor for the development of cardiovascular disease.` '7 In diabetic subjects studies have shown an association between increased fibrinogen and microvascular and macrovascular complications.89 Numerous methods can be used for the estimation of plasma fibrinogen including thrombin clotting techniques,'0'3 heat precipitation,'4 salt precipitation'5 and immunochemical assay. '6 17 With the aim of establishing a plasma fibrinogen method to be used for risk factor analysis in the routine evaluation of patients we compared the result of fibrinogen assayed by a thrombin clotting technique and by an immunochemical method (radial immunodiffusion) in a group of normal healthy controls and hyperlipidaemic patients.
Methods
All reagents were analytical grade unless otherwise stated. Thrombin 5000 NIH units/phial was obtained from Rorer Pharmaceuticals, Eastbourne, Sussex. Protamine sulphate was obtained from BDH Ltd, Poole, Dorset. Phosphate buffered saline (pH 6-4) was prepared by dissolving KH2PO4 (0-91 g), Na2HPO4
(0-47 g), and NaCl (8-5 g) in distilled water to a final volume of one litre.
Blood was collected from 14 patients attending the lipid clinic at the Westminster Hospital (mean age 63 years, range 49-73 years). Five of the patients were receiving treatment for hypertension and nine had clinical evidence of macrovascular disease. All patients were being treated for hyperlipidaemia (by diet and drugs). No patient had diabetes; one patient was a current smoker. Blood was also collected from 21 healthy normolipidaemic laboratory volunteers aged 29-40 years. None of the volunteers was taking any medication and none had a history of vascular disease. Samples were collected into sodium citrate, 38 g/l ( 6 It is unlikely that the improved discrimination by radial immunodiffusion can be attribu- ted to differences in the amount of in vivo fibrinolysis as only three samples had detectable fibrin D-dimer domain by latex immunoassay. It could be argued that the samples from the patients contained more early fibrinogen degradation products (X, Y, and E) which are not detected by the latex immunoassay. If present these products would almost certainly cause overestimation of fibrinogen by radial immunodiffusion because of antigenic cross reaction with the intact fibrinogen molecules. Our data do not support this view, however, because the plasma fibrinogen results by radial immunodiffusion are lower in both healthy controls and hyperlipidaemic patients compared with results using the turbidimetric thrombin clotting technique.
Discrepancies between plasma fibrinogen assay by radial immunodiffusion and the thrombin clotting technique have been previously described following surgery or extensive intravascular thrombosis and during the menstrual cycle.22 None of the patients in our study, however, had recently had surgery or extensive intravascular thrombosis. During the menstrual phase, immunoreactive fibrinogen is higher than fibrinogen assayed by the thrombin clotting technique because of the increased concentration of circulating fibrinogen fragments generated by the breakdown of the endometrium. 22 In our study concentrations of immunoreactive fibrinogen were actually lower than thrombin clottable fibrinogen in both the patient and control groups which makes it unlikely that there were increased amounts of circulating fibrin fragments in our group of patients or controls.
The difference in the median plasma fibrinogen concentrations between the normal healthy controls and hyperlipidaemic patients was similar and was about 1 g/l. It is the lower variance of fibrinogen values seen in the controls when fibrinogen is assayed by radial immunodiffusion that is the major reason for the improved discrimination between the normal controls and hyperlipidaemic patients when using the radial immunodiffusion assay. It is unlikely that a difference in assay precision could be responsible for this as both methods have similar precision.
Our study needs to be extended to ascertain whether similar discrepancies are observed between immunochemical methods and the clot weight assay"2 and with heat or salt precipitation.4 15 
